Press releases
- Quest Diagnostics Elects Robert B. Carter, CIO of FedEx Corporation, to Board of Directors
- Quest Diagnostics Declares Quarterly Cash Dividend
- Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests
- Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
- Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
- Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI
- Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024
- Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease
- Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay
- Study in Frontiers in Neurology Affirms Amyloid Blood Test Can Help Identify Patients Who May Forgo Imaging Evaluation for Alzheimer's Disease
More ▼
Key statistics
As of last trade QUEST DIAGNODRN (Q1UE34:SAO) traded at 328.82, -2.85% below its 52-week high of 338.47, set on May 30, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | 360.93 |
Offer | 365.04 |
Previous close | 328.82 |
Average volume | -- |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 5.75 BRL |
---|---|
Annual div yield (ADY) | 1.75% |
Div ex-date | Apr 05 2024 |
Div pay-date | Apr 26 2024 |
Next div ex-date | Jul 05 2024 |
Next div pay-date | Jul 26 2024 |
Data delayed at least 15 minutes, as of May 24 2024 16:42 BST.
More ▼